AQUAXYL Hydra concept An innovative moisturizing and restructuring technology www.seppic.com
HYDRACNCEPT A "Moisturizing and Restructuring" efficacy achieved by the harmonization of sin s hydrous flow. DRY AND FRAGILE SKIN MISTURIZED AND RESISTANT SKIN s reserves s loss reserves loss Hydrous flow imbalance (Causes: environment, irritating products, ageing) Alteration of desquamation Disorganisation of sin microrelief Hydrous flow balance Normalization of desquamation Reorganisation of sin microrelief Harmonization of hydrous flow AQUAXYL : Moisturizing and Restructuring effect AQUAXYL improves water reserves and limits water loss. Desquamation is balanced, microrelief is smoothed. Moisturized and restructured, the sin is better equipped to combat external aggressions. Visual improvement of sin surface (normalization of desquamation and smoothing of microrelief) Increase of water RESERVES Improvement of epidermal water content ( electrical conductance) Increase of dermal water reservoirs ( GAGs) Decrease of water LSS Improvement barrier function ( ceramide synthesis) Decrease of Trans Epidermal Loss ( TEWL) GAGs : Glycosaminoglycans TEWL: Trans Epidermal Loss
PTIMIZATIN F WATER RESERVES Improvement of epidermal water content*: Corneometry. In vivo effect Increase of dermal water reservoirs**: Stimulation of GAGs synthesis ( and chondroitine sulphate) on fibroblasts: in vitro effect % of hydration increase % of / hydration placebo increase / placebo % of GAGs increase / control + 18% + 18% % of hydration increase / placebo 15 1 15 chondroitin sulphate chondroitin sulphate + 18% 1 8 8 1 % of GAGs increase 1 / control 15 chondroitin sulphate 1 + 55% + 55% 4 % of hydration increase / placebo + 47% 8 4 5 + 47% 5 + 18% 1 + % + % + 55% 4 15 chondroitin + 47% 1 D (8h after D (8h D after 15 D 15 D 5 sulphate D AQUAXYL TM AQUAXYL + % TM 8,1 %,1 %,1 % a.m.,1 % a.m. 1 D (8h after D 15 D + 55% AQUAXYL TM Aquaxyl 4 significantly improves epidermis hydration versus + 47% Aquaxyl significantly stimulates 5,1 %,1 % a.m. placebo from the first application. This effect is confirmed the glycosaminoglycans + content. % after 15 days and one month of treatment. The trapped water is available within the sin. Immediate D (8h and afterlong term D moisturizing 15 effect. D AQUAXYL TM,1 %,1 % a.m. % of GAGs increase /% control of GAGs increase / control DECREASE F WATER LSS Barrier % of ceramide function synthesis % of improvement ceramide increase / synthesis control increase - Increase / control of ceramide synthesis on human sin tissue**: 14 14 % of ceramide synthesis increase / control Ex vivo effect 1 14 1 8 % of ceramide 8 synthesis increase / control 1 14 8 4 + 19% 4* + 8% + 8% 1 4 + 8% 8 AQUAXYL TM AQUAXYL Glycerin TM Placebo Glycerin Placebo % % %,1 % 4 AQUAXYL TM Glycerin Placebo % + 8% % AQUAXYL TM Glycerin Placebo % %,1 % Aquaxyl significantly stimulates ceramide synthesis. The barrier function is improved. Decrease of Trans Epidermal Loss (TEWL)*: D (8h In vivo after effect D (8h D after 15 D D 15 D D (8h after D 15 D - 5-5 - 1 D - 5 (8h after D 15 D 1-15,1 % - 1-15 - 5 % of TEWL decrease %/ of placebo - 15 TEWL decrease / placebo,1 % - 1 % of TEWL decrease / placebo - 15 Aquaxyl decreases significantly sin water loss % of TEWL decrease versus / placebo after one month of treatment. Sin is stronger and more resistant. VISUAL IMPRVEMENT F SKIN SURFACE Desquamation normalization: In vivo effect Sin microrelief smoothing: In vivo effect Corneocytes removal (D squama) at D 1 month treatment with placebo 1 month treatment with AQUAXYL (EU95 formula) Sin print at D 1 month treatment with placebo 1 month treatment with AQUAXYL (EU95 formula) + 5% improvement of desquamation with % Aquaxyl versus placebo (visual scale) From the first month of treatment, Aquaxyl balances the desquamation. The sin is visibly moisturized. + % of sin networ improvement with % Aquaxyl versus placebo (visual scale) From the first month of treatment, Aquaxy reorganizes sin microrelief. The barrier function is reinforced. The sin is visibly moisturized. *Tests significative results in comparison to the placebo **Tests significative results in comparison to the control
FRMULATIN GUIDELINES AQUAXYL is a water-soluble and transparent liquid. It can be easily used in all type of galenic forms (including colourless and odorless emulsions, transparent lotions...) for moisturizing, anti-ageing or restructuring benefits. SEPPIC s Expertise in sugar chemistry dedicated to the continuous improvement of hydration. Glucose and xylitol association for the synthesis of a new structure from a vegetable origin. "FRCE AND HYDRATIN" sin care - EU95 EU95 formula tested in vivo against placebo. - 5 volunteers with dry sin - one month of treatment (on legs). Glucose (vegetable origin/wheat) + Xylitol (vegetable origin/wood) A B C D MNTANV 8 1,5 % MNTANV 1,5 % LANL 188 15, % Aqua / Up to 1 % SIMULGEL EG 1, % AQUAXYL, % Parfum / Fragrance, % SEPICIDE HB, % Imidazolidinyl urea, % CH - CH CH Xylitylpolyglucosides CH - Aquaxyl is stable, even at high temperature. It can be easily incorporated at any step of the formulation process. CH CH n CH - + xylitan RECMMENDED DSAGE LEVEL % TLERANCE Excellent tolerance of AQUAXYL up to 5% + xylitol CH CH CH -
Nota : The analytical specifications warranted are only those mentioned on the certificate of analysis supplied with each delivery of the product. Except as set forth above, SEPPIC* maes no warranties, whether express, implied or statutory, as to the product which is the subject of this document. Without limiting the generality of the foregoing, SEPPIC* maes no warranty of merchantability of the product or of the fitness of the product for any particular purpose. Buyer assumes all ris and liability resulting from the use or sale of the product, whether singly or in combination with other goods. The information set forth herein is furnished free of charge and is based on technical data that SEPPIC* believes to be reliable. It is intended for use by persons having technical sill and at their own discretion and ris. Since conditions of use are outside SEPPIC* s control, SEPPIC* maes no warranties, express or implied, and assumes no liability in connection with any use of this information. Nothing herein is to be taen as a license to operate under or a recommendation to infringe any patents. * SEPPIC being: SEPPIC S.A. Terrasse Bellini 98 Puteaux FRANCE Tel. : + () 1 4 91 4 info.seppic@airliquide.com SEPPIC UK Ltd 5 Salisbury Road P Box 8 - Hounslow TW4 SH ENGLAND Tel. : + 44 8 577 88 u.seppic@airliquide.com SEPPIC Italia Srl SEPPIC Italia Srl Via Quarenghi 7 151 Milano ITALIA Tel. : + 9 8911 italy.seppic@airliquide.com SEPPIC GmbH von-der-wettern-str.7 51149 Köln GERMANY Tel. : + 49 () -898- germany.seppic@airliquide.com Head ffice 75, quai d rsay 757 Paris FRANCE SEPPIC Inc., Two Bridges Road, suite 1 Fairfield, New Jersey 74-15 USA Tel. : + 1 97 88 5597 us.seppic@airliquide.com SEPPIC Brasil Rua Libero Badaro, 18 8 andar Centro 18- Sao Paolo SP BRASIL Tel. : + 55 11 4 911 brasil.seppic@airliquide.com SEPPIC Colombia SAS Calle 71 n 1-4 Edificio rbe 71 of 41 Bogota CLMBIA Tel: + 571 7 44 48 colombia.seppic@airliquide.com 11 SEPPIC Aquaxyl is registered as Trade Mar of SEPPIC SEPPIC* a subsidiary of the AIR LIQUIDE group SEPPIC Japan ffice Air Liquide Japan s office Granpar Tower -4-1 Shibaura Minato-u, Toyo 18-859 JAPAN Tel : + 81 414 75 japan.seppic@airliquide.com SEPPIC Poland ffice CCIF Ul. Wido 8 - Varsovie PLAND Tel : + 48 9 8 7 poland.seppic@airliquide.com www.seppic.com SEPPIC Asia Singapore Lower Delta Road # 1 11 Cendex Centre Singapore 198 SINGAPRE Tel. : + 5 78 711 singapore.seppic@airliquide.com SEPPIC Dubai ffice Dubai Airport Free Zone West Wing 4, B Bloc, Suite 144, Dubai U.A.E. P.. Box 548 Tel : + 971 (4) 9555 dubai.seppic@airliquide.com SEPPIC Mumbai B-11, Knox Plaza MindSpace,ff Chincholi bunder rd Malad (W) Mumbai - 44 INDIA Tel : + 91 4744 india.seppic@airliquide.com SEPPIC China Room 51 Jin Tai Building 58 South Mao Ming Road Shanghai CHINA Tel. : + 8 (1) 4 1 49 china.seppic@airliquide.com 484-E/GB// September 11 - photo: SEPPIC